EN ESTA EDICIÓN: Vacunación oral contra el cólera en la isla de La Española | Segunda reunión anual de la Comisión Regional de Monitoreo y Reverificación de la Eliminación del Sarampión y la Rubéola | Certificados digitales como ejemplo de transformación digital en la inmunización | La O...PS desarrolla un programa piloto de implantación de indicadores de monitoreo y evaluación con el Estado Plurinacional de Bolivia mediante datos de su Registro Nominal de Vacunación Electrónico | Clasificación final de casos en la Región de las Américas, 2022.
more
Este manual constituye un esfuerzo por ser una herramienta de primera
mano, que demarca de manera sencilla los lineamientos para la atención
del paciente con diagnóstico de Enfermedad Chagas. Está basado en
evidencias clínicas recientes y recomendación de expertos nacionales e
internacional...es y está adaptado a las condiciones y características
epidemiológicas del país.
more
PLOS ONE | DOI:10.1371/journal.pone.0142290 November 9, 2015; 1 / 16
Accessed January 22, 2019.
This updated version include important research that has added to our knowledge about effective treatments for
child and adolescent depression. Its goal is to help parents and families make informed decisions about getting the best care for a child with depression. For ...easy use, it is presented in Frequently Asked Questions (FAQ) format.
more
Update, 23 de junio de 2022
Rev Panam Salud Publica. 2021;45:e74.
Some characteristics of patients and healthcare providers influence treatment success in MDR-TB cases. Physicians’ and nurses’ knowledge about MDR-TB must be improved, and follow-up of MDR-TB patients who are living with HIV and of those affiliated with the... subsidized health insurance scheme in Colombia must be strengthened, as these patients have a lower likelihood of a successful treatment outcome.
more
Guía de tratamiento farmacológico y manejo deescenarios clínicos de casos de COVID-19 – enero 2022 Guía de tratamiento farmacológico y manejo deLeer más
Mpox continues to affect people around the world. A new framework released today by WHO will guide health authorities, communities and other stakeholders in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from ani...mals to humans.
Mpox is a viral illness caused by the monkeypox virus (MPXV). It can cause a painful rash, enlarged lymph nodes and fever. Most people fully recover, but some get very sick. The virus transmits from person to person through close, including sexual, contact. It also has animal reservoirs in east, central and west Africa, where spillovers from animals to humans can occasionally occur, sparking further outbreaks.
There are two different clades of the virus: clade I and clade II. Clade I outbreaks are deadlier than clade II outbreaks.
A major emergence of mpox linked to clade II began in 2017, and since 2022, has spread to all regions of the world. Between July 2022 and May 2023, the outbreak was declared a Public Health Emergency of International Concern. While that outbreak has largely subsided, cases and deaths continue to be reported today, illustrating that low-level transmission continues around the world.
Currently, there is also a major outbreak of clade I virus in the Democratic Republic of the Congo (DRC), where cases have been on the rise for decades. Since the beginning of the year, over 6500 cases and 345 deaths have been reported in the DRC. Almost half of these are among children under the age of 15 years.
The Strategic framework for enhancing prevention and control of mpox (2024–2027) provides a roadmap for health authorities, communities, and stakeholders worldwide to control mpox outbreaks in every context, advance mpox research and access to countermeasures, and to minimize zoonotic transmission.
more
Clinical care for severe acute respiratory infection: toolkit: COVID-19 adaptation
BUKO Pharma-Kampagne has investigated the causes and consequences of antibiotic resistance in India, South Africa, Tanzania and Germany. Together with our partners we collected data and did interviews with numerous stakeholders. The outcome is presented in a brochure that is now available in English...
Resistant bacteria are spreading worldwide. In collaboration with partners in India, Tanzania, South Africa and Germany, we have investigated the causes and consequences of this spread.2 This Pharma-Brief Special presents the results. It examines the risks for humans, animals and the environment. It focuses on local problems and approaches, international interactions and the re-sponsibility of doctors, farmers and consumers.
more
Orientations provisoires 19 juillet 2021
Chromoblastomycosis (CMB) is a chronic fungal infection of the skin and the subcutaneous tissue caused by a transcutaneous traumatic inoculation of a specific group of dematiaceous fungi occurring mainly in tropical and subtropical zones worldwide. If not diagnosed at early stages, patients with CBM... require long term therapy with systemic antifungals, sometimes associated with physical methods. Unlike other neglected endemic mycoses, comparative clinical trials have not been performed for this disease. Nowadays, therapy is based on a few open trials and on expert opinion. Itraconazole either as monotherapy or associated with other drugs, or with physical methods, is widely used. Recently, photodynamic therapy has been successfully employed in combination with antifungals in patients presenting with CBM. In the present revision the most used therapeutic options against CBM are reviewed as well as the several factors that may have impact on the patient's outcome.
more
Addressing comorbidities and risk factors for tuberculosis (TB) is a crucial component of the World Health Organization (WHO)’s End TB Strategy. This WHO operational handbook on tuberculosis. Module 6: tuberculosis and comorbidities aims to support countries in scaling up people-centred care, ...based on the latest WHO recommendations on TB and key comorbidities, and drawing upon additional evidence, best practices and inputs from various experts and stakeholders obtained during WHO processes. It is intended for use by people working in ministries of health, particularly TB programmes and the relevant departments or programmes responsible for comorbidities and health-related risk factors for TB such as HIV, diabetes, undernutrition, substance use, and tobacco use, as well as programmes addressing mental health and lung health.
more
As the Americas undergo profound demographic change and there are more persons aged 65 years or older than children younger than 5 years, it is crucial to recognize that national immunization programs must be redesigned to ensure comprehensive protection for individuals across the lifespan. By adopt...ing a life course approach (LCA) to immunization, vaccination programs can be tailored to close immunity gaps at different stages of life. The life course approach foresees the establishment of multiple strategies to reduce missed opportunities for vaccination according to age group. This technical document explains the key concepts of the LCA with a focus on immunization by vaccination, as well as the underlying biological mechanisms that require the application different vaccines at different life stages according to changes to the immune system and in the epidemiological situation of a community.
more
Joining efforts to control two trelated global epidemics.
Orientations provisoires
6 avril 2020
Le présent document résume les recommandations de l’OMS sur l’utilisation rationnelle de l’équipement de protection individuelle (EPI) dans les établissements de santé et lors des soins à domicile, ainsi que lors de la manipulation des cargaison...s; il évalue également les perturbations qui touchent actuellement la chaîne d’approvisionnement mondiale et les éléments à considérer pour la prise de décisions en cas de grave pénurie d’EPI.
more